Enterprise Value
-4.688M
Cash
204.7M
Avg Qtr Burn
-31.79M
Short % of Float
3.51%
Insider Ownership
0.30%
Institutional Own.
52.52%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
afami-cel (Afamitresgene autoleucel) (ADP-A2M4) Details Myxoid/Round cell liposarcoma, Cancer | BLA Acceptance for review | |
ADP-A2M4CD8 (MAGE A4) +/- nivolumab Details Cancer, Ovarian cancer | Phase 2 Data readout | |
Lete-cel (NY-ESO) Details Myxoid/Round cell liposarcoma, Sarcoma | Phase 2 Data readout | |
Gavo-cel (TC-210) (Mesothelin) + nivolumab Details Solid tumor/s, Ovarian cancer, Cancer | Phase 1/2 Data readout | |
TC-510 Details Cancer, Ovarian cancer, Colorectal cancer , Pancreatic cancer, Mesothelioma, Triple-negative breast cancer | Phase 1/2 Data readout | |
ADP-A2M4CD8 (MAGE A4) +/- nivolumab Details Head and neck cancer, Bladder cancer, Cancer, Solid tumor/s, Urothelial cancer | Phase 1 Data readout | |
afami-cel (afamitresgene autoleucel) (ADP-A2M4) + pembro Details Head and neck cancer, Homozygous familial hypercholesterolemia, Cancer, Solid tumor/s | Failed Discontinued | |
TC-110 (CD19) Details Non-Hodgkin lymphoma, Leukemia, Acute lymphoblastic leukemia, Diffuse large B cell lymphoma, Cancer | Failed Discontinued | |
ADP-A2AFP Details Hepatocellular carcinoma, Cancer | Failed Discontinued |